JP2012513990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012513990A5 JP2012513990A5 JP2011543458A JP2011543458A JP2012513990A5 JP 2012513990 A5 JP2012513990 A5 JP 2012513990A5 JP 2011543458 A JP2011543458 A JP 2011543458A JP 2011543458 A JP2011543458 A JP 2011543458A JP 2012513990 A5 JP2012513990 A5 JP 2012513990A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- aryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 125000000623 heterocyclic group Chemical group 0.000 claims 62
- 125000003118 aryl group Chemical group 0.000 claims 44
- 125000001072 heteroaryl group Chemical group 0.000 claims 44
- 125000003545 alkoxy group Chemical group 0.000 claims 36
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- -1 COOR1a Chemical group 0.000 claims 22
- 125000005842 heteroatom Chemical group 0.000 claims 17
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000004104 aryloxy group Chemical group 0.000 claims 12
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 12
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- PRULMJKVHATYQP-UHFFFAOYSA-N 4-(quinolin-2-ylmethyl)piperazine-1-carbaldehyde Chemical group C1CN(C=O)CCN1CC1=CC=C(C=CC=C2)C2=N1 PRULMJKVHATYQP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 235000021229 appetite regulation Nutrition 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 0 *c1c(*)nc(*)[n]1C(N(*)*)=O Chemical compound *c1c(*)nc(*)[n]1C(N(*)*)=O 0.000 description 17
- BDVYXMRYPRBKMG-UHFFFAOYSA-N CN(C1CCOCC1)C([n]1cnc(-c2c[n+]([U-])ccc2)c1)=O Chemical compound CN(C1CCOCC1)C([n]1cnc(-c2c[n+]([U-])ccc2)c1)=O BDVYXMRYPRBKMG-UHFFFAOYSA-N 0.000 description 2
- HSLOZRQCLQVPAH-UHFFFAOYSA-N CN(C1CCCCC1)C([n]1cnc(-c2cc[n+](C)cc2)c1)=O Chemical compound CN(C1CCCCC1)C([n]1cnc(-c2cc[n+](C)cc2)c1)=O HSLOZRQCLQVPAH-UHFFFAOYSA-N 0.000 description 1
- OUOUTIJTFIDAHJ-UHFFFAOYSA-N CN(C1CCOCC1)C([n]1cnc(-c2cnccc2)c1)=O Chemical compound CN(C1CCOCC1)C([n]1cnc(-c2cnccc2)c1)=O OUOUTIJTFIDAHJ-UHFFFAOYSA-N 0.000 description 1
- XUEBIYRDHFIJGD-UHFFFAOYSA-N COc(cc(cc1)-c(nc2)c[n]2C(NC2CCCC2)=O)c1F Chemical compound COc(cc(cc1)-c(nc2)c[n]2C(NC2CCCC2)=O)c1F XUEBIYRDHFIJGD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14064008P | 2008-12-24 | 2008-12-24 | |
| US61/140,640 | 2008-12-24 | ||
| US15928109P | 2009-03-11 | 2009-03-11 | |
| US61/159,281 | 2009-03-11 | ||
| US17471209P | 2009-05-01 | 2009-05-01 | |
| US61/174,712 | 2009-05-01 | ||
| US22116609P | 2009-06-29 | 2009-06-29 | |
| US61/221,166 | 2009-06-29 | ||
| US24247209P | 2009-09-15 | 2009-09-15 | |
| US61/242,472 | 2009-09-15 | ||
| PCT/PT2009/000080 WO2010074588A2 (en) | 2008-12-24 | 2009-12-23 | Pharmaceutical compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237957A Division JP2015071622A (ja) | 2008-12-24 | 2014-11-25 | 医薬品 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012513990A JP2012513990A (ja) | 2012-06-21 |
| JP2012513990A5 true JP2012513990A5 (https=) | 2013-02-14 |
| JP5657566B2 JP5657566B2 (ja) | 2015-01-21 |
Family
ID=42288334
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543458A Expired - Fee Related JP5657566B2 (ja) | 2008-12-24 | 2009-12-23 | 医薬品 |
| JP2014237957A Pending JP2015071622A (ja) | 2008-12-24 | 2014-11-25 | 医薬品 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237957A Pending JP2015071622A (ja) | 2008-12-24 | 2014-11-25 | 医薬品 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9353082B2 (https=) |
| EP (1) | EP2382012A2 (https=) |
| JP (2) | JP5657566B2 (https=) |
| KR (1) | KR101715190B1 (https=) |
| CN (2) | CN105399731A (https=) |
| AR (1) | AR075111A1 (https=) |
| AU (1) | AU2009330821B2 (https=) |
| BR (2) | BRPI0923819B1 (https=) |
| CA (1) | CA2747784C (https=) |
| IL (1) | IL213747A (https=) |
| MX (1) | MX342128B (https=) |
| NZ (1) | NZ593418A (https=) |
| RU (1) | RU2553451C2 (https=) |
| SG (1) | SG172301A1 (https=) |
| TW (1) | TWI469979B (https=) |
| WO (1) | WO2010074588A2 (https=) |
| ZA (1) | ZA201104336B (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| WO2012007500A2 (de) * | 2010-07-15 | 2012-01-19 | Bayer Cropscience Ag | Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| CA2806701A1 (en) * | 2010-07-29 | 2012-02-02 | Bial - Portela & Ca, S.A. | Process for the synthesis of substituted urea compounds |
| EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| CA2830958A1 (en) * | 2011-04-06 | 2012-10-11 | The Scripps Research Institute | N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
| US8921398B2 (en) * | 2011-06-09 | 2014-12-30 | Boehringer Ingelheim International Gmbh | N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions and uses thereof |
| KR102507287B1 (ko) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| WO2014017936A2 (en) * | 2012-07-24 | 2014-01-30 | Bial- Portela & Ca, S.A. | Urea compounds and their use as enzyme inhibitors |
| WO2014017938A2 (en) | 2012-07-27 | 2014-01-30 | BIAL - PORTELA & Cª, S.A. | Process for the synthesis of substituted urea compounds |
| AU2014293731B2 (en) | 2013-07-24 | 2018-03-08 | Bial - Portela & Ca, S.A. | Imidazolecarboxamides and their use as FAAH inhibitors |
| AU2014296894A1 (en) | 2013-08-01 | 2016-02-25 | Bial - Portela & Ca, S.A. | Urea compounds and their use as FAAH enzyme inhibitors |
| GB201313903D0 (en) | 2013-08-02 | 2013-09-18 | Bial Portela & Ca Sa | Urea compounds and their use as enzyme inhibitors |
| GB201401198D0 (en) | 2014-01-24 | 2014-03-12 | Bial Portela & Ca Sa | Process for the syntheis of substituted urea compounds |
| US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| US10681909B2 (en) | 2014-08-29 | 2020-06-16 | Fmc Corporation | Herbicidal triazoles |
| CN104292172B (zh) * | 2014-09-12 | 2016-08-17 | 浙江理工大学 | 一种苯并三氮唑类衍生物及其制备方法 |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| CN108601769B (zh) * | 2015-11-20 | 2021-09-03 | H.隆德贝克有限公司 | 吡唑化合物及其制备和使用方法 |
| WO2017087858A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017096315A1 (en) | 2015-12-02 | 2017-06-08 | The Scripps Research Institute | TRIAZOLE DAGL(α) INHIBITORS |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| RU2720203C1 (ru) * | 2017-01-20 | 2020-04-27 | Пфайзер Инк. | 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl |
| CN110198944A (zh) | 2017-01-23 | 2019-09-03 | 辉瑞大药厂 | 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物 |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) * | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| DK3630744T3 (da) | 2017-05-23 | 2023-03-06 | H Lundbeck As | Pyrazol-magl-inhibitorer |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| CA3185336A1 (en) * | 2017-11-06 | 2019-05-09 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation |
| JP2021518855A (ja) * | 2018-03-02 | 2021-08-05 | ユニヴェルシテ ド ローザンヌ | Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体 |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| CN108912112A (zh) * | 2018-08-14 | 2018-11-30 | 李敬敬 | 一种化合物、制备方法以及其在治疗疼痛中的应用 |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| JP7397491B2 (ja) | 2018-10-23 | 2023-12-13 | 国立研究開発法人科学技術振興機構 | ＰＰＡＲδ活性化剤 |
| SG11202105250TA (en) * | 2018-11-20 | 2021-06-29 | Sironax Ltd | Cyclic Ureas |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| WO2023023156A1 (en) * | 2021-08-18 | 2023-02-23 | The Regents Of The University Of California | Acid ceramidase inhibitors and uses thereof |
| CN115707699B (zh) * | 2021-08-18 | 2025-08-19 | 中国医学科学院医药生物技术研究所 | 一组抗骨质疏松的化合物及其应用 |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| US12234205B1 (en) | 2024-05-22 | 2025-02-25 | King Saud University | Sulfonylhydrazide derivatives as anticancer agents |
| WO2025245484A1 (en) * | 2024-05-23 | 2025-11-27 | Thymofox Inc. | Foxn1 activators |
| WO2026006527A1 (en) * | 2024-06-26 | 2026-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Covalent inhibitors of jak2 jh2 domain |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3248398A (en) * | 1961-01-05 | 1966-04-26 | Bayer Ag | Substituted ureas |
| US3940484A (en) * | 1971-12-07 | 1976-02-24 | The Boots Company Limited | Insecticidal compositions and methods of combatting insects using substituted imidazoles |
| GB1408877A (en) * | 1971-12-07 | 1975-10-08 | Boots Co Ltd | Substituted imidazoles and their use as pesticides |
| US3932444A (en) * | 1972-04-28 | 1976-01-13 | E. I. Du Pont De Nemours & Co. | 4-Imidazolylsulfonylimidazoles |
| CA1035188A (en) * | 1974-08-15 | 1978-07-25 | Eastman Kodak Company | Blocked development restrainers |
| DE2834879A1 (de) * | 1978-08-07 | 1980-02-21 | Schering Ag | 1,2,3-triazolcarbonsaeureamide, verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel |
| CA1126999A (en) * | 1978-10-20 | 1982-07-06 | Michael J. Simons | Use of azole compounds with a n,n disubstituted carbamoyl group on a ring nitrogen as development restrainer precursors in photographic elements |
| GB8426367D0 (en) * | 1984-10-18 | 1984-11-21 | Shell Int Research | Heteroaromatic ether herbicides |
| FR2579596B1 (fr) * | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
| JPH0753716B2 (ja) * | 1986-07-02 | 1995-06-07 | 吉富製薬株式会社 | イミダゾ−ルカルボキサミド誘導体 |
| DD295852A5 (de) * | 1988-07-18 | 1991-11-14 | Arzneimittelwerk Dresden Gmbh,De | Verfahren zur herstellung von acylureido-benzylpenicillinen und deren salzen |
| JPH02124559A (ja) * | 1988-11-02 | 1990-05-11 | Fuji Photo Film Co Ltd | ネガ型ハロゲン化銀写真感光材料 |
| US4942248A (en) * | 1988-12-01 | 1990-07-17 | Ppg Industries, Inc. | Tertiary-alkyl esters of 1H-benzotriazole-1-carboxylic acids |
| JPH03246206A (ja) * | 1990-02-21 | 1991-11-01 | Sumitomo Chem Co Ltd | トリハロイミダゾール誘導体を有効成分とするゴキブリ用殺虫剤 |
| JPH0559017A (ja) * | 1990-10-26 | 1993-03-09 | Ube Ind Ltd | １，２，３−トリアゾール誘導体、その製法及び有害生物防除剤 |
| US5633377A (en) | 1990-12-28 | 1997-05-27 | Neurogen Corporation | 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands |
| FR2671083B1 (fr) | 1990-12-31 | 1994-12-23 | Inst Nat Sante Rech Med | Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques. |
| JPH0649041A (ja) * | 1992-07-28 | 1994-02-22 | Mitsubishi Petrochem Co Ltd | カルバモイルトリアゾール誘導体、それを有効成分とする除草剤およびその製造方法 |
| US6262093B1 (en) * | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
| US5798374A (en) * | 1995-06-07 | 1998-08-25 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith |
| JPH11338100A (ja) * | 1998-05-22 | 1999-12-10 | Fuji Photo Film Co Ltd | 記録材料 |
| MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| JP2001302640A (ja) * | 2000-04-19 | 2001-10-31 | Tokuyama Corp | カルボニルジアゾール誘導体の製造方法 |
| US6472133B1 (en) * | 2000-06-13 | 2002-10-29 | Eastman Kodak Company | Silver halide element with improved high temperature storage |
| US6372421B1 (en) * | 2000-06-13 | 2002-04-16 | Eastman Kodak Company | Photothermographic imaging element having improved contrast and methods of image formation |
| CA2422916A1 (en) * | 2000-09-26 | 2002-04-04 | The University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| AU2002216314A1 (en) * | 2000-10-12 | 2002-04-22 | Scott A Henderson | Heterocyclic angiogenesis inhibitors |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| CA2440211A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| US6787555B2 (en) * | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| US6727364B2 (en) * | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| JP2003005323A (ja) * | 2001-06-20 | 2003-01-08 | Konica Corp | 熱現像写真感光材料及び画像形成方法 |
| US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| KR20040068240A (ko) * | 2001-12-14 | 2004-07-30 | 노보 노르디스크 에이/에스 | 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용 |
| JP2003327532A (ja) * | 2002-05-10 | 2003-11-19 | Takeda Chem Ind Ltd | ペプチダーゼ阻害剤 |
| EP1558591B1 (en) * | 2002-10-07 | 2014-05-07 | The Regents of The University of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| BR0314980A (pt) * | 2002-10-08 | 2005-08-09 | Scripps Research Inst | Inibidores de hidrolase de amida de ácido graxo |
| US7208504B2 (en) | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
| DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
| CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| PE20050226A1 (es) | 2003-06-04 | 2005-05-18 | Aventis Pharma Sa | Productos aril-heteroaromaticos y composiciones que los contienen |
| WO2005014576A1 (ja) * | 2003-08-12 | 2005-02-17 | Takeda Pharmaceutical Company Limited | イソキノリノン誘導体、その製造法および用途 |
| WO2006032852A1 (en) * | 2004-09-20 | 2006-03-30 | Biolipox Ab | Pyrazole compounds useful uin the treatment of inflammation |
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| AR055831A1 (es) * | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| PE20070099A1 (es) * | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| TW200738701A (en) | 2005-07-26 | 2007-10-16 | Du Pont | Fungicidal carboxamides |
| WO2007030680A2 (en) * | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| DE102005049953A1 (de) * | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| DE102005049954A1 (de) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| TW200732320A (en) * | 2005-10-31 | 2007-09-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| US20110172230A1 (en) * | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| FR2915197B1 (fr) | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| FI20075264A0 (fi) * | 2007-04-18 | 2007-04-18 | Kuopion Yliopisto | Heterosykliset fenyylikarbamaatit uusina FAAH-inhibiittoreina |
| FR2915199B1 (fr) | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| JP5583592B2 (ja) * | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009117444A1 (en) | 2008-03-17 | 2009-09-24 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| JP5620365B2 (ja) * | 2008-03-21 | 2014-11-05 | エンソン インコーポレイテッド | 多官能分子システムを用いた積層体への金属の接着促進 |
| PT3733383T (pt) * | 2019-05-02 | 2023-03-15 | Teepack Spezialmaschinen Gmbh & Co Kg | Dispositivo e processo para a produção de uma saqueta dotada de um invólucro, contendo um material passível de infusão |
-
2009
- 2009-12-23 JP JP2011543458A patent/JP5657566B2/ja not_active Expired - Fee Related
- 2009-12-23 CN CN201510829064.7A patent/CN105399731A/zh active Pending
- 2009-12-23 EP EP09801307A patent/EP2382012A2/en not_active Withdrawn
- 2009-12-23 SG SG2011045465A patent/SG172301A1/en unknown
- 2009-12-23 WO PCT/PT2009/000080 patent/WO2010074588A2/en not_active Ceased
- 2009-12-23 TW TW98144476A patent/TWI469979B/zh not_active IP Right Cessation
- 2009-12-23 BR BRPI0923819-0A patent/BRPI0923819B1/pt not_active IP Right Cessation
- 2009-12-23 CN CN200980157449.6A patent/CN102333568B/zh not_active Expired - Fee Related
- 2009-12-23 US US13/141,205 patent/US9353082B2/en not_active Expired - Fee Related
- 2009-12-23 MX MX2011006643A patent/MX342128B/es active IP Right Grant
- 2009-12-23 AU AU2009330821A patent/AU2009330821B2/en not_active Ceased
- 2009-12-23 AR ARP090105108A patent/AR075111A1/es not_active Application Discontinuation
- 2009-12-23 RU RU2011129416/04A patent/RU2553451C2/ru active
- 2009-12-23 BR BR122013027950A patent/BR122013027950A2/pt not_active Application Discontinuation
- 2009-12-23 KR KR1020117017329A patent/KR101715190B1/ko not_active Expired - Fee Related
- 2009-12-23 CA CA2747784A patent/CA2747784C/en active Active
- 2009-12-23 NZ NZ593418A patent/NZ593418A/xx not_active IP Right Cessation
-
2011
- 2011-06-10 ZA ZA2011/04336A patent/ZA201104336B/en unknown
- 2011-06-23 IL IL213747A patent/IL213747A/en not_active IP Right Cessation
-
2014
- 2014-11-25 JP JP2014237957A patent/JP2015071622A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012513990A5 (https=) | ||
| CA2493225A1 (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| JP2006504658A5 (https=) | ||
| JP2013510120A5 (https=) | ||
| JP2018515555A5 (https=) | ||
| JP2011505347A5 (https=) | ||
| JP2019513770A5 (https=) | ||
| JP2013513613A5 (https=) | ||
| JP2013537203A5 (https=) | ||
| NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| CA2476983A1 (en) | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma | |
| TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| JP2015508103A5 (https=) | ||
| CA2566544A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| JP2013544860A5 (https=) | ||
| JP2012513416A5 (https=) | ||
| TW200738729A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| JP2010515750A5 (https=) | ||
| JP2015535847A5 (https=) | ||
| JP2014505723A5 (https=) | ||
| JP2017502063A5 (https=) | ||
| JP2013544854A5 (https=) | ||
| JP2007500222A5 (https=) | ||
| JP2012524110A5 (https=) |